Eyegene, Inc. engages in the research and development of pharmaceutical products. Its products include curing technologies and vaccines for diabetic retinopathy, decubitus ulcer, cervical cancer, and adjuvant immunotherapy. The company was founded on June 23, 2000 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company